---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-099356"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:52:49.198444+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio raises ~$6M in registered direct offering of 4M shares/pre-funded warrants at $1.50/share

## Summary
- Offering comprises 3.15M shares and 850K pre-funded warrants at $1.50 per share (warrant price $1.4999); gross proceeds ~$6M.
- Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease, working capital, and general corporate purposes.
- H.C. Wainwright acts as exclusive placement agent; 7% cash fee plus 200K warrants exercisable at $2.20 per share for 5 years.
- Officers and directors subject to 45-day lock-up from closing date, which is expected on or about October 13-14, 2025.

## SEC filing metadata
- accession: 0001104659-25-099356
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465925099356/0001104659-25-099356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465925099356/tm2528502d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-099356
- JSON: https://secwatch.observer/filing/0001104659-25-099356.json
- Plain text: https://secwatch.observer/filing/0001104659-25-099356.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.